Last reviewed · How we verify
mFOLFOX6 or CAPOX
mFOLFOX6 or CAPOX is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin to target rapidly dividing cancer cells.
mFOLFOX6 or CAPOX is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin to target rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer.
At a glance
| Generic name | mFOLFOX6 or CAPOX |
|---|---|
| Also known as | 5-Fu-leucovorin-oxaliplatin or xeloda-oxaliplatin |
| Sponsor | LI XIN-XIANG |
| Drug class | Platinum-based chemotherapy |
| Target | DNA replication machinery |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The regimen works by inhibiting DNA synthesis and function in cancer cells, leading to cell death. Oxaliplatin interferes with DNA replication, while 5-fluorouracil and leucovorin inhibit thymidylate synthase, a key enzyme in DNA synthesis.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colon cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea and vomiting
- Fatigue
- Anemia
Key clinical trials
- SAMe in Prevention of Oxaliplatin-associated Liver Injury (PHASE2)
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (PHASE1, PHASE2)
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (PHASE3)
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (PHASE2, PHASE3)
- Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (PHASE2)
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (PHASE1)
- Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (PHASE2)
- COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |